"Sympatholytics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
| Descriptor ID |
D013565
|
| MeSH Number(s) |
D27.505.696.663.050.850
|
| Concept/Terms |
Sympatholytics- Sympatholytics
- Sympatholytic Agents
- Agents, Sympatholytic
- Sympatholytic Drugs
- Drugs, Sympatholytic
- Sympathetic-Blocking Agents
- Agents, Sympathetic-Blocking
- Sympathetic Blocking Agents
Sympatholytic Effect- Sympatholytic Effect
- Effect, Sympatholytic
- Sympatholytic Effects
- Effects, Sympatholytic
|
Below are MeSH descriptors whose meaning is more general than "Sympatholytics".
Below are MeSH descriptors whose meaning is more specific than "Sympatholytics".
This graph shows the total number of publications written about "Sympatholytics" by people in this website by year, and whether "Sympatholytics" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sympatholytics" by people in Profiles.
-
Nwazue VC, Paranjape SY, Black BK, Biaggioni I, Diedrich A, Dupont WD, Robertson D, Raj SR. Postural tachycardia syndrome and inappropriate sinus tachycardia: role of autonomic modulation and sinus node automaticity. J Am Heart Assoc. 2014 Apr 10; 3(2):e000700.
-
Cheyuo C, Jacob A, Wang P. Ghrelin-mediated sympathoinhibition and suppression of inflammation in sepsis. Am J Physiol Endocrinol Metab. 2012 Feb 01; 302(3):E265-72.
-
Logan RW, Arjona A, Sarkar DK. Role of sympathetic nervous system in the entrainment of circadian natural-killer cell function. Brain Behav Immun. 2011 Jan; 25(1):101-9.
-
Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 2008 Feb 27; 5:8.
-
Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, Robertson D, Biaggioni I. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006 Mar; 47(3):522-6.
-
Reuben SS, Steinberg RB, Madabhushi L, Rosenthal E. Intravenous regional clonidine in the management of sympathetically maintained pain. Anesthesiology. 1998 Aug; 89(2):527-30.
-
Spodick DH, Meyer MB, St Pierre JR. The effect of -adrenergic blockade on cardiac responses to orthostatic stress. Am Heart J. 1972 May; 83(5):719-22.
-
Anthony JR, Jick H, Spodick DH. Control of persistent ventricular ectopic beats by alprenolol, a new beta-adrenergic blocking agent. Am Heart J. 1969 May; 77(5):598-602.